KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|10|8|813-823

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.10, Iss.8, 2010-12, pp. : 813-823

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-Egfr Therapy in Colorectal Cancer: How to Choose The Right Patient

By  

Current Drug Targets, Vol. 10, Iss. 10, 2009-10 ,pp. : 1033-1040

Bentham Science Publishers

Access to resources Recommend Favorite

Patient-Tailored Treatments with Anti-EGFR Monoclonal Antibodies in Advanced Colorectal Cancer: KRAS and Beyond

By  

Current Cancer Drug Targets, Vol. 12, Iss. 4, 2012-04 ,pp. : 316-328

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice

By Scartozzi Mario   Pierantoni Chiara   Berardi Rossana   Squadroni Michela   Cascinu Stefano  

Expert Opinion on Therapeutic Targets, Vol. 10, Iss. 2, 2006-04 ,pp. : 281-287

Informa Healthcare

Access to resources Recommend Favorite

Anti-EGFR Strategy for Colorectal Cancer: Searching for the Real Target

By  

Letters in Drug Design & Discovery, Vol. 3, Iss. 8, 2006-10 ,pp. : 541-543

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients

By  

Current Cancer Drug Targets, Vol. 10, Iss. 1, 2010-02 ,pp. : 68-79

Bentham Science Publishers

Access to resources Recommend Favorite